Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes - RECORD


The goal of the trial was to evaluate the effect of rosiglitazone plus metformin or sulfonylurea compared with metformin plus sulfonylurea on cardiovascular (CV) outcomes in patients with type 2 diabetes who had inadequate glycemic control while receiving metformin or sulfonylurea monotherapy.